Navigation Links
Enzyme explains angina in diabetics
Date:11/27/2012

In a new study published in the scientific journal Circulation, scientists at Karolinska Institutet and Karolinska University Hospital in Sweden show that an enzyme called arginase might have a key part to play in the development of cardiovascular disease in patients who already have type II diabetes. According to the team, arginase prevents the formation of protective nitrogen oxide in the blood vessels, and treatments that inhibit this enzyme reduce the risk of angina in diabetics.

"The fact that we could demonstrate the presence of arginase in several types of cell in the vessel wall gives us an entirely new explanatory model for the development of complications in these patients," says lead investigator Professor John Pernow.

Complications in diabetes patients result from constrictions of the blood vessels caused by plaque deposits on the vessel walls (atherosclerosis). The ensuing reduction in blood flow and oxygen supply can lead to angina, myocardial infarction or stroke, and possible amputation. Atherosclerosis is more common in people who smoke and who have high levels of blood lipids, although the risk is most pronounced in patients with diabetes. The reason for this correlation between diabetes and cardiovascular disease has largely eluded scientists and there is still no specific treatment for these complications.

In this present study, the researchers analysed the function of the arginase enzyme (or protein) in the blood vessels of patients with both type II diabetes and angina and found that it prevents the formation of protective molecule nitric oxide in the vessel wall. After introducing a substance already known to inhibit the enzyme, they observed a significant improvement in blood vessel function in these patients.

A comparative analysis showed that the arginase inhibitor did not have the same positive effect on patients with angina but without type II diabetes, and had no effect at all on healthy controls.

"Nitric oxide has a very important function to perform in the vessel walls," says Professor Pernow. "Apart from dilating them, it prevents the formation of plaque. For some reason, however, the mechanism is impaired in people with diabetes."

A total of 48 patients were included in the study and the team is now planning a larger follow-up study to confirm their results and develop treatments using arginase inhibitors. The study was financed by the Swedish Research Council, the Swedish Heart-Lung Foundation, the NovoNordisk Foundation, the European Foundation for the Study of Diabetes, and the Gustav V and Queen Victoria Foundation.


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Gateway enzyme for chemicals from catnip to cancer drug
2. Structure of enzyme unravelled providing basis for more accurate design of chemotherapeutic drugs
3. Mayo Clinic researchers identify new enzyme to fight Alzheimers disease
4. Compounds activate key cancer enzyme to interfere with tumor formation
5. Enzymes implicated in disease processes attack one another instead of harming body proteins
6. Clemson researchers collect and reuse enzymes while maintaining bioactivity
7. Enzyme offers new therapeutic target for cancer drugs
8. Enzyme corrects more than 1 million faults in DNA replication
9. Discovery explains how cellular pathways converge to regulate food intake and body weight
10. Inherited DNA change explains overactive leukemia gene
11. Psychological Science explains uproar over prostate-cancer screenings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... DKT International, one of the ... is pleased to release their 2015 global impact data. In 2015, DKT served ... maternal deaths and 3.8 million unsafe abortions across 21 countries worldwide. , ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, delivering comprehensive ... Prescription Drug survey , an employee benefits survey measuring how Central ... December 2015, indicates that employers are turning to consumer directed health care and ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
(Date:5/25/2016)... Atlanta GA (PRWEB) , ... May 25, 2016 ... ... workplace solutions builder, has announced that it will join America's leading engineers at ... will be held at the Georgia World Congress Center. , Engineers, speakers ...
(Date:5/24/2016)... ... May 24, 2016 , ... BTC Media, ... blockchain event, Distributed: Health, to be held in Nashville, Tennessee on September 7, ... A 24-hour Hackathon preceding the event will host teams from around the world, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual ... fistula intervention   OrbusNeich, a global company ... expanded its portfolio to include products to treat peripheral ... the company,s first entry devices for lower limb and ...
(Date:5/24/2016)... 24, 2016 Dutch surgeons have launched a ... the world and treat patients on a global scale. Medical professionals ... Asia and the US have already signed ... and networking in a totally secure environment. Education  ... zone working together with a surgeon at Harvard to treat a ...
Breaking Medicine Technology: